NASDAQ

Callan JMB Inc. (CJMB)

361 Thanks from members

Callan JMB Inc. (CJMB) exhibits a mixed to fragile market reputation, weighed down by a $7.97M annual net loss, a Nasdaq bid-price deficiency notice, and severe past shareholder dilution, balanced against an expanded $75M equity purchase facility and niche life sciences cold chain logistics demand.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →